Dual targeting of JAK2 and ERK interferes with the myeloproliferative neoplasm clone and enhances therapeutic efficacy

Myeloproliferative neoplasms (MPN) show dysregulated JAK2 signaling. JAK2 inhibitors provide clinical benefits, but compensatory activation of MAPK pathway signaling impedes efficacy. We hypothesized that dual targeting of JAK2 and ERK1/2 could enhance clone control and therapeutic efficacy. We empl...

Descripción completa

Detalles Bibliográficos
Autores principales: Brkic, Sime, Stivala, Simona, Santopolo, Alice, Szybinski, Jakub, Jungius, Sarah, Passweg, Jakob R., Tsakiris, Dimitrios, Dirnhofer, Stefan, Hutter, Gregor, Leonards, Katharina, Lischer, Heidi E. L., Dettmer, Matthias S., Neel, Benjamin G., Levine, Ross L., Meyer, Sara C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478661/
https://www.ncbi.nlm.nih.gov/pubmed/34480104
http://dx.doi.org/10.1038/s41375-021-01391-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8478661/
https://www.ncbi.nlm.nih.gov/pubmed/34480104
http://dx.doi.org/10.1038/s41375-021-01391-2

Ejemplares similares